Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Declan O'Rourke

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|May 23, 2024
Stratifying risk of disease in haematuria patients using machine learning techniques to improve diagnosticsAnna Drożdż, Brian Duggan, Mark W Ruddock, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 14, 2018
Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancerHeather Nesbitt, Yingjie Sheng, Sukanta Kamila, et al.
Frontiers in Oncology|October 10, 2022
Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specificBrian Duggan, Declan O'Rourke, Neil Anderson, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|April 2, 2021
Exploiting a Rose Bengal-bearing, oxygen-producing nanoparticle for SDT and associated immune-mediated therapeutic effects in the treatment of pancreatic cancerDean Nicholas, Heather Nesbitt, Sian Farrell, et al.
BMC Medicine|January 19, 2013
Collectives of diagnostic biomarkers identify high-risk subpopulations of hematuria patients: exploiting heterogeneity in large-scale biomarker dataFrank Emmert-Streib, Funso Abogunrin, Ricardo de Matos Simoes, et al.
Cancer|September 16, 2011
The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuriaFunso Abogunrin, Hugh F O'Kane, Mark W Ruddock, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 3, 2017
Magnetically responsive microbubbles as delivery vehicles for targeted sonodynamic and antimetabolite therapy of pancreatic cancerYingjie Sheng, Estelle Beguin, Heather Nesbitt, et al.
Seizure|May 10, 2026
Uridine-responsive epileptic encephalopathy: Precision treatment across the age spectrum - a case seriesGurdeep Sekhon, Ana Perez Caballero, Christin Eltze, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2018
AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated SurvivalEmilio Cosimo, Anuradha Tarafdar, Michael W Moles, et al.
Plos One|February 18, 2015
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itselfCian M McCrudden, Martin G O'Rourke, Kim E Cherry, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|May 23, 2024
Stratifying risk of disease in haematuria patients using machine learning techniques to improve diagnosticsAnna Drożdż, Brian Duggan, Mark W Ruddock, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 14, 2018
Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancerHeather Nesbitt, Yingjie Sheng, Sukanta Kamila, et al.
Frontiers in Oncology|October 10, 2022
Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specificBrian Duggan, Declan O'Rourke, Neil Anderson, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|April 2, 2021
Exploiting a Rose Bengal-bearing, oxygen-producing nanoparticle for SDT and associated immune-mediated therapeutic effects in the treatment of pancreatic cancerDean Nicholas, Heather Nesbitt, Sian Farrell, et al.
BMC Medicine|January 19, 2013
Collectives of diagnostic biomarkers identify high-risk subpopulations of hematuria patients: exploiting heterogeneity in large-scale biomarker dataFrank Emmert-Streib, Funso Abogunrin, Ricardo de Matos Simoes, et al.
Cancer|September 16, 2011
The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuriaFunso Abogunrin, Hugh F O'Kane, Mark W Ruddock, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 3, 2017
Magnetically responsive microbubbles as delivery vehicles for targeted sonodynamic and antimetabolite therapy of pancreatic cancerYingjie Sheng, Estelle Beguin, Heather Nesbitt, et al.
Seizure|May 10, 2026
Uridine-responsive epileptic encephalopathy: Precision treatment across the age spectrum - a case seriesGurdeep Sekhon, Ana Perez Caballero, Christin Eltze, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2018
AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated SurvivalEmilio Cosimo, Anuradha Tarafdar, Michael W Moles, et al.
Plos One|February 18, 2015
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itselfCian M McCrudden, Martin G O'Rourke, Kim E Cherry, et al.
Pageof 5